SCHEMBL386120

SCHEMBL386120

[c]1ccc2c(Oc3ccccc3)cccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 2/20 0.40
KMT2A Q03164 4/20 0.39
LMNA P02545 3/20 0.39
MEN1 O00255 2/20 0.39
MITF O75030 1/20 0.39
POLB P06746 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 1/20 0.37
TSHR P16473 2/20 0.37
LTA4H P09960 1/20 0.37
DPP4 P27487 1/20 0.37
HRH1 P35367 1/20 0.35
CTNNB1 P35222 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.35
SIRT1 Q96EB6 1/20 0.35
SIRT3 Q9NTG7 1/20 0.35
MAPT P10636 2/20 0.35
HPGD P15428 2/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL27705785 0.81 KCNA3 (0.56) KCNA3KMT2ALMNAMEN1MITF
SCHEMBL8702780 0.80 KMT2A (0.41) KCNA3KMT2ALMNAMEN1MITF
SCHEMBL37789 0.80 MEN1 (0.44) KCNA3KMT2ALMNAMEN1MITF
SCHEMBL28029061 0.79 KCNA3 (0.44) KCNA3KMT2ALMNAMEN1MITF
SCHEMBL441860 0.79 KCNA3 (0.58) KCNA3KMT2ALMNAMEN1MITF
SCHEMBL29860318 0.79 KCNA3 (0.58) KCNA3KMT2ALMNAMEN1MITF
SCHEMBL386606 0.77 NQO1 (0.44) LMNAMAPTHPGDSMN1; SMN2KDM4E
SCHEMBL7198014 0.76 KCNA3 (0.31) KCNA3HPGDKDM4EALDH1A1
SCHEMBL386823 0.76 MRGPRX4 (0.49) KCNA3KMT2AL3MBTL1GAALTA4H
SCHEMBL4719645 0.74 NQO1 (0.37) KMT2ALMNAMEN1MITFPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101650-B2 Method for treating a immunology-related disease DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-24 US disclosed
US-8067396-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2011-11-29 US disclosed
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2010-02-11 US disclosed
US-20090326038-A1 Method for treating a immunology-related disease SANKYO COMPANY, LIMITED (JP) 2009-12-31 US disclosed
US-7638551-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2009-12-29 US disclosed
US-20070142335-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2007-06-21 US disclosed
US-20070105933-A1 Amino alcohol compounds SANKYO COMPANY, LIMITED (JP) 2007-05-10 US disclosed
EP-1300405-B1 AMINO ALCOHOL DERIVATIVES SANKYO CO (JP) 2007-04-18 EP disclosed
US-7199150-B2 Amino alcohol compounds SANKYO COMPANY, LIMITED (JP) 2007-04-03 US disclosed
US-6964976-B2 Amino alcohol derivatives SANKYO COMPANY, LIMITED (JP) 2005-11-15 US disclosed
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these SANKYO COMPANY, LIMITED (JP) 2005-02-24 US disclosed
EP-1471054-A1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE Sankyo Company, Limited (JP) 2004-10-27 EP disclosed
US-20040132784-A1 Amino alcohol derivatives SANKYO COMPANY, LIMITED (JP) 2004-07-08 US disclosed
US-6723745-B2 PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE IN WARM BLOODED ANIMAL SANKYO COMPANY, LIMITED (JP) 2004-04-20 US disclosed
US-20030236297-A1 Amino alcohol derivatives SANKYO COMPANY, LIMITED (JP) 2003-12-25 US disclosed
EP-1300405-A1 AMINO ALCOHOL DERIVATIVES Sankyo Company, Limited (JP) 2003-04-09 EP disclosed
EP-1070703-A1 Cyclobutene derivatives Sankyo Company Limited (JP) 2001-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236297-A1 Amino alcohol derivatives CD4, ADH1C, ADH1A KCNA3 3000/4885KMT2A 1760/4885LMNA 3703/4885
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these PHOSPHO1, CD4, FCGRT KCNA3 4044/4885KMT2A 3736/4885LMNA 4143/4885
US-20040132784-A1 Amino alcohol derivatives CD4, ADH1C, ADH1A KCNA3 3000/4885KMT2A 1760/4885LMNA 3703/4885
US-20090326038-A1 Method for treating a immunology-related disease C3AR1, HRH3, HRH2 KCNA3 2415/4885KMT2A 2185/4885LMNA 3060/4885
US-20070105933-A1 Amino alcohol compounds ADH1C, C9, SSB KCNA3 2887/4885KMT2A 2919/4885LMNA 1187/4885
US-20070142335-A1 Amino alcohol compounds or phosphonic acid derivatives thereof HRH3, C3AR1, HRH4 KCNA3 4255/4885KMT2A 3339/4885LMNA 2699/4885
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof PHOSPHO1, ADH1C, ADH1A KCNA3 3747/4885KMT2A 1437/4885LMNA 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.